一个功能化的素双网络纳米平台,通过触发反应性氧物种自我循环来增强癌症治疗
Wenda Wang1, Shaofei Nie1, Chunyi Luo2
1College of Materials Science and Engineering, Central South University of Forestry and Technology, Changsha 410004, China.
International journal of biological macromolecules
|May 22, 2025
概括
这项研究引入了用于癌症治疗的新型纳米系统,通过创建自我维持的活性氧物种循环来增强抗瘤疗效,并减少副作用,从而增强化学动力疗法.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术 纳米技术
- 癌症治疗 癌症治疗
背景情况:
- 化学动力学疗法 (CDT) 对瘤治疗具有前景,克服了光动力学和声动力学疗法的局限性.
- 在CDT的挑战包括反应性氧物种 (ROS) 的短暂性和非特异性药物释放.
- 开发有针对性和持续的药物输送系统对于有效的CDT至关重要.
研究的目的:
- 构建一个双网络纳米系统,用于增强化学动力学治疗和治疗结肠癌的化疗.
- 解决ROS不稳定性和CDT中非特异性药物释放的局限性.
- 创建一个自我维持的ROS生成周期,以改善抗瘤效果.
主要方法:
- 一个双网络纳米系统 (EAMLVP@PTX) 的制造,使用基酸修饰的红素与乙烯酸罗利共聚合物接种,装载有paclitaxel.
- 利用酸性瘤微环境进行纳米粒子电荷逆转和阴阳性内细胞分裂.
- 利用ellagic酸在结肠癌细胞中的线粒体向,诱导ROS生产和药物释放.
主要成果:
- 该纳米系统在酸性瘤环境中证明了电荷逆转,促进了细胞吸收.
- 酸促进了线粒体的向,启动了ROS的产生和药物释放.
- 建立了一个自我维持的ROS循环,导致编程细胞死亡和显著的抗瘤疗效在体外和体内.
- 纳米系统显示了最小的副作用.
结论:
- 开发的EAMLVP@PTX纳米系统有效地克服了ROS过渡性和CDT中的非特异性药物释放挑战.
- 该纳米系统对结肠癌具有显著的协同化学/化学动力学治疗效应.
- 这一战略为增强癌症治疗提供了一个非常有前途的方法,并提高了安全性.
更多相关视频
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
16.7K
09:01Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy
Published on: May 22, 2020
3.1K
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Electron Transport Chain: Complex I and II
12.2K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
12.2K
